Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
作者： James Bentley , Marc Buyse , Rita Nigam , Genevieve M Weir , Lisa D MacDonald
DOI: 10.1080/2162402X.2015.1026529
关键词:
摘要: DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin highly expressed in many tumor types has reported prognostic value. To generate tumor-specific immune response, a novel cancer was formulated DepoVax platform (DPX-Survivac) using survivin HLA class I peptides. Safety potency of DPX-Survivac tested combination with immune-modulator metronomic cyclophosphamide ovarian patients. All the patients receiving therapy produced antigen-specific responses; higher dose treatment generating significantly magnitude responses. Strong T cell responses were associated differentiation naive cells into central/effector memory (CM/EM) late differentiated (LD) polyfunctional CD4+ CD8+ cells. This approach enabled rapid de novo activation/expansion provided strong rationale for further testing to determine clinical benefits this activation. These data represent vaccine-induced activation setting self-tumor antigen previously described only animal models.
elsevier.com
sci-hub.se 参考文章(37)
Alvaro Lladser, Carlos Sanhueza, Rolf Kiessling, Andrew F.G. Quest, Is Survivin the Potential Achilles’ Heel of Cancer? Advances in Cancer Research. ,vol. 111, pp. 1- 37 ,(2011) , 10.1016/B978-0-12-385524-4.00001-5
Nicholas P Restifo, Luca Gattinoni, Lineage relationship of effector and memory T cells. Current Opinion in Immunology. ,vol. 25, pp. 556- 563 ,(2013) , 10.1016/J.COI.2013.09.003
François Ghiringhelli, Cedric Menard, Pierre Emmanuel Puig, Sylvain Ladoire, Stephan Roux, François Martin, Eric Solary, Axel Le Cesne, Laurence Zitvogel, Bruno Chauffert, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy. ,vol. 56, pp. 641- 648 ,(2007) , 10.1007/S00262-006-0225-8
W. Joost Lesterhuis, John B. A. G. Haanen, Cornelis J. A. Punt, Cancer immunotherapy – revisited Nature Reviews Drug Discovery. ,vol. 10, pp. 591- 600 ,(2011) , 10.1038/NRD3500
Michael G. Kenward, James H. Roger, Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood Biometrics. ,vol. 53, pp. 983- 997 ,(1997) , 10.2307/2533558
Kimberly D. Brewer, Kerry Lake, Nicole Pelot, Marianne M. Stanford, Drew R. DeBay, Andrea Penwell, Genevieve M. Weir, Mohan Karkada, Marc Mansour, Chris V. Bowen, Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine. ,vol. 32, pp. 6956- 6962 ,(2014) , 10.1016/J.VACCINE.2014.10.058
Lothar H. Finke, Kerry Wentworth, Brent Blumenstein, Natalie S. Rudolph, Hyam Levitsky, Axel Hoos, Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. ,vol. 25, ,(2007) , 10.1016/J.VACCINE.2007.06.067
Volker Lennerz, Stefanie Gross, Elisa Gallerani, Cristiana Sessa, Nicolas Mach, Steffen Boehm, Dagmar Hess, Lotta von Boehmer, Alexander Knuth, Adrian F. Ochsenbein, Ulrike Gnad-Vogt, Juergen Zieschang, Ulf Forssmann, Thomas Woelfel, Eckhart Kaempgen, Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors Cancer Immunology, Immunotherapy. ,vol. 63, pp. 381- 394 ,(2014) , 10.1007/S00262-013-1516-5
Andrzej T. Galecki, General class of covariance structures for two or more repeated factors in longitudinal data analysis Communications in Statistics-theory and Methods. ,vol. 23, pp. 3105- 3119 ,(1994) , 10.1080/03610929408831436
Srinivas Nagaraj, Dmitry I Gabrilovich, Myeloid derived suppressor cells OncoImmunology. ,vol. 2, pp. e24117- ,(2013) , 10.4161/ONCI.24117